Literature DB >> 32473755

Involvement of activin a receptor type 1 (ACVR1) in the pathogenesis of primary focal hyperhidrosis.

Jian-Bo Lin1, Jian-Feng Chen2, Fan-Cai Lai2, Xu Li2, Jin-Bao Xie2, Yuan-Rong Tu2, Ming-Qiang Kang3.   

Abstract

The pathogenesis of primary focal hyperhidrosis (PFH) is still not clear. PFH is thought to be a genetic disease. Whether activin A receptor type 1 (ACVR1) is involved in the pathogenesis of PFH is unknown. In this study, the expression of ACVR1 in sweat glands of patients with PAH was detected by western blot and immunofluorescence. The primary sweat gland cells obtained from primary axillary hyperhidrosis (PAH) patients were transfected with acvr1 vector. Cell proliferation, apoptosis and cell cycling of gland cells were measured after transfection with acvr1 vector. The mRNA and protein expression of aquaporin 5 (AQP5) and Na:K:2Cl Cotransporter 1 (NKCC1/SLC12A2) were detected. Our data showed that ACVR1 expression in axillary sweat gland tissue of PAH patients was significantly higher than that of normal control group. The function of ACVR1 was further investigated in the gland cells obtained from PAH patients. Compared with NC group, ACVR1 overexpression significantly promoted the proliferation of sweat gland cells and inhibited the apoptosis of sweat gland cells. Meanwhile, ACVR1 overexpression significantly reduced the percentage of cells in G0/G1 and G2/M phases, and increased the percentage of cells in S phase. In addition, ACVR1 overexpression significantly promoted the expression of AQP5 and NKCC1 at both mRNA and protein levels. Together, ACVR1 expression is related to PFH and ACVR1 overexpression can promote the proliferation of sweat gland cells and inhibit apoptosis by promoting the expression of AQP5 and NKCC1.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Activated protein a receptor 1; Aquaporin 5; Primary local hyperhidrosis; Sodium potassium chloride cotransporter 1

Year:  2020        PMID: 32473755     DOI: 10.1016/j.bbrc.2020.05.052

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2.

Authors:  Minh H Nguyen; Onur Atasoylu; Liangxing Wu; Kanishk Kapilashrami; Michelle Pusey; Karen Gallagher; Cheng-Tsung Lai; Peng Zhao; Joseph Barbosa; Kai Liu; Chunhong He; Colin Zhang; Evan D Styduhar; Michael R Witten; Yaoyu Chen; Luping Lin; Yan-Ou Yang; Maryanne Covington; Sharon Diamond; Swamy Yeleswaram; Wenqing Yao
Journal:  ACS Med Chem Lett       Date:  2022-06-22       Impact factor: 4.632

2.  Antagonist of Chrna1 prevents the pathogenesis of primary focal hyperhidrosis.

Authors:  Jian-Bo Lin; Nan-Long Lin; Xu Li; Ming-Qiang Kang
Journal:  Ann Clin Transl Neurol       Date:  2022-04-08       Impact factor: 5.430

Review 3.  Accumulated Knowledge of Activin Receptor-Like Kinase 2 (ALK2)/Activin A Receptor, Type 1 (ACVR1) as a Target for Human Disorders.

Authors:  Takenobu Katagiri; Sho Tsukamoto; Mai Kuratani
Journal:  Biomedicines       Date:  2021-06-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.